Hepion Pharmaceuticals (HEPA) awards 299K options to director
Rhea-AI Filing Summary
Hepion Pharmaceuticals, Inc. (HEPA) reported that director Gary S. Stetz II received a grant of 299,000 stock options on August 19, 2026. The options have an exercise price of $0.08 per share, are exercisable beginning August 19, 2027, and expire on August 19, 2036. Following this grant, he holds 299,000 derivative securities directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Stetz Gary S. II
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 299,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options — 299,000 shares (Direct)
Key Figures
Stock options granted: 299,000 options
Exercise price: $0.08 per share
Underlying common stock: 299,000 shares
+3 more
6 metrics
Stock options granted
299,000 options
Grant to director Gary S. Stetz II on August 19, 2026
Exercise price
$0.08 per share
Conversion or exercise price of granted stock options
Underlying common stock
299,000 shares
Shares of common stock underlying the stock options
Total derivative securities after transaction
299,000 options
Directly owned by Gary S. Stetz II following the grant
Exercise date
August 19, 2027
Date from which the options are exercisable
Expiration date
August 19, 2036
Expiration of the granted stock options
Key Terms
Stock Options, exercise price, derivative securities, expiration date
4 terms
Stock Options financial
"security_title: "Stock Options" for the reported derivative grant"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"conversion_or_exercise_price set at an exercise price of 0.0800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
derivative securities financial
"reported as derivative securities with underlying common stock"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
expiration date financial
"expiration_date specified as 2036-08-19 for the options"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What insider transaction did HEPA disclose for Gary S. Stetz II?
HEPA disclosed that director Gary S. Stetz II received a grant of 299,000 stock options on August 19, 2026, as reported on Form 4.
What is the exercise price of the new stock options granted at HEPA?
The stock options granted to Gary S. Stetz II have an exercise price of $0.08 per share for the underlying Hepion Pharmaceuticals, Inc. common stock.
When can the newly granted HEPA stock options be exercised?
The options granted to Gary S. Stetz II become exercisable on August 19, 2027, as disclosed for this Form 4 derivative acquisition.
When do Gary S. Stetz II’s HEPA stock options expire?
The reported stock options expire on August 19, 2036, giving Gary S. Stetz II a 10-year term from the grant date to exercise them, subject to their terms.
How many HEPA derivative securities does Gary S. Stetz II hold after this transaction?
After this grant, Gary S. Stetz II holds 299,000 derivative securities (stock options) of Hepion Pharmaceuticals, Inc., all reported as directly owned.
Is this HEPA insider transaction a purchase or a grant?
This HEPA insider transaction is a grant or award of stock options coded as “A” on Form 4, indicating an acquisition of derivative securities rather than an open-market purchase.
AI-generated analysis. How Rhea-AI works. Not financial advice.
